For the second year, DT Consulting assessed the state of digital excellence (DX) in clinical operations at the world’s largest pharmaceutical firms by surveying 18 senior clinical ops leaders. Analysis of the data reveals that the industry’s overall digital maturity, while still good, has not progressed over the past year. Most pharma firms have substantially shifted their priorities towards clinical research sites and now consider clinical trial experiences as a top component of digital strategy success. The view is a bit different at best-in-class companies, which continue to focus on internal enablement. Firms also reported difficulties in financially sustaining long-term digital initiatives. To navigate these challenges, firms should explore collaborative solutions, share best practices, and strategically address financial hurdles by balancing quick wins with long-term projects.

Sign up to our latest insights

By checking this box, you agree to receive survey invitations and our latest insights.